Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A2 | P19784 | 19/20 | 0.43 |
| ▸ | CSNK2B | P67870 | 18/20 | 0.43 |
| ▸ | CSNK2A1 | P68400 | 12/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.42 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.42 |
| ▸ | CSNK2A3 | Q8NEV1 | 3/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26049073 | 0.94 | CSNK2A2 (0.47) | CSNK2A2CSNK2BCSNK2A1PIM1PIM2 | |
| SCHEMBL25369974 | 0.89 | CSNK2A2 (0.51) | CSNK2A2CSNK2BCSNK2A1PIM1PIM2 | |
| SCHEMBL29900380 | 0.89 | CSNK2A2 (0.51) | CSNK2A2CSNK2BCSNK2A1PIM1PIM2 | |
| SCHEMBL26049116 | 0.88 | CSNK2A2 (0.40) | CSNK2A2CSNK2BCSNK2A1PIM1PIM2 | |
| SCHEMBL26049113 | 0.88 | CSNK2A2 (0.40) | CSNK2A2CSNK2BCSNK2A1PIM1PIM2 | |
| SCHEMBL29900217 | 0.88 | CSNK2A2 (0.41) | CSNK2A2CSNK2BCSNK2A1PIM1PIM2 | |
| SCHEMBL25369359 | 0.88 | CSNK2A2 (0.41) | CSNK2A2CSNK2BCSNK2A1PIM1PIM2 | |
| SCHEMBL29900230 | 0.87 | CSNK2A2 (0.40) | CSNK2A2CSNK2BCSNK2A1PIM1PIM2 | |
| SCHEMBL25370447 | 0.87 | CSNK2A2 (0.40) | CSNK2A2CSNK2BCSNK2A1PIM1PIM2 | |
| SCHEMBL26049067 | 0.86 | CSNK2A2 (0.43) | CSNK2A2CSNK2BCSNK2A1PIM1PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250097-A1 | BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF | Apollo Therapeutics Limited (GB) | 2023-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250097-A1 | BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF | CSNK1A1, CSNK1D, CSNK2A1 | CSNK2A2 5/4885CSNK2B 8/4885CSNK2A1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.